 Jacob Painter
Concepts (192)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 19 | 2024 | 501 | 3.330 |
Why?
| | Veterans | 7 | 2023 | 629 | 1.810 |
Why?
| | Chronic Pain | 9 | 2024 | 147 | 1.790 |
Why?
| | Neuralgia | 2 | 2023 | 58 | 1.560 |
Why?
| | Breast Neoplasms | 3 | 2023 | 1248 | 1.280 |
Why?
| | Antipsychotic Agents | 2 | 2018 | 247 | 1.050 |
Why?
| | Drug Overdose | 4 | 2022 | 154 | 1.010 |
Why?
| | Evidence-Based Practice | 3 | 2023 | 110 | 0.970 |
Why?
| | Fibromyalgia | 2 | 2013 | 18 | 0.900 |
Why?
| | Retrospective Studies | 21 | 2024 | 6432 | 0.900 |
Why?
| | Pain | 4 | 2022 | 405 | 0.810 |
Why?
| | United States | 19 | 2023 | 5217 | 0.790 |
Why?
| | Humans | 52 | 2024 | 54284 | 0.780 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2020 | 21 | 0.760 |
Why?
| | Inappropriate Prescribing | 2 | 2017 | 20 | 0.730 |
Why?
| | Cost-Benefit Analysis | 3 | 2017 | 291 | 0.710 |
Why?
| | Opioid-Related Disorders | 5 | 2023 | 367 | 0.710 |
Why?
| | Pharmacists | 2 | 2018 | 152 | 0.700 |
Why?
| | Lymphedema | 1 | 2019 | 43 | 0.690 |
Why?
| | Students, Pharmacy | 2 | 2018 | 147 | 0.690 |
Why?
| | Calcium Channel Blockers | 1 | 2019 | 72 | 0.690 |
Why?
| | Critical Illness | 4 | 2021 | 344 | 0.680 |
Why?
| | Guidelines as Topic | 1 | 2019 | 125 | 0.670 |
Why?
| | Tramadol | 3 | 2024 | 29 | 0.670 |
Why?
| | Aged | 17 | 2023 | 10054 | 0.650 |
Why?
| | Serotonin Syndrome | 1 | 2018 | 7 | 0.640 |
Why?
| | Intensive Care Units | 4 | 2021 | 231 | 0.640 |
Why?
| | Vasopressins | 4 | 2019 | 42 | 0.620 |
Why?
| | Benzodiazepines | 1 | 2018 | 72 | 0.620 |
Why?
| | Shock, Septic | 4 | 2021 | 80 | 0.610 |
Why?
| | Seizures | 1 | 2019 | 208 | 0.610 |
Why?
| | Etomidate | 1 | 2016 | 6 | 0.600 |
Why?
| | Off-Label Use | 1 | 2017 | 27 | 0.590 |
Why?
| | Vasoconstrictor Agents | 4 | 2019 | 88 | 0.590 |
Why?
| | Cannabis | 1 | 2019 | 147 | 0.590 |
Why?
| | Anesthetics, Intravenous | 1 | 2016 | 26 | 0.590 |
Why?
| | Hyperalgesia | 1 | 2017 | 56 | 0.580 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2016 | 22 | 0.580 |
Why?
| | Community Pharmacy Services | 1 | 2018 | 70 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 486 | 0.570 |
Why?
| | Psychotherapy | 1 | 2017 | 106 | 0.570 |
Why?
| | Phenols | 1 | 2018 | 120 | 0.570 |
Why?
| | Female | 24 | 2023 | 28441 | 0.570 |
Why?
| | Cohort Studies | 7 | 2022 | 1543 | 0.570 |
Why?
| | Curriculum | 2 | 2024 | 429 | 0.560 |
Why?
| | Adult | 19 | 2024 | 14207 | 0.560 |
Why?
| | Depression | 3 | 2022 | 595 | 0.560 |
Why?
| | Middle Aged | 17 | 2023 | 13088 | 0.550 |
Why?
| | Smoking Cessation | 1 | 2019 | 316 | 0.540 |
Why?
| | Mental Disorders | 2 | 2018 | 451 | 0.530 |
Why?
| | HIV Infections | 2 | 2016 | 394 | 0.510 |
Why?
| | United States Department of Veterans Affairs | 6 | 2018 | 315 | 0.510 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 333 | 0.490 |
Why?
| | Mental Health Services | 1 | 2017 | 242 | 0.490 |
Why?
| | Telemedicine | 2 | 2017 | 449 | 0.490 |
Why?
| | Ambulatory Care | 1 | 2015 | 230 | 0.480 |
Why?
| | Respiration, Artificial | 1 | 2016 | 285 | 0.480 |
Why?
| | Pain Management | 6 | 2023 | 155 | 0.460 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2017 | 394 | 0.460 |
Why?
| | Male | 22 | 2023 | 27334 | 0.450 |
Why?
| | Case-Control Studies | 3 | 2023 | 1228 | 0.450 |
Why?
| | Norepinephrine | 3 | 2018 | 119 | 0.450 |
Why?
| | Medicare | 3 | 2023 | 241 | 0.450 |
Why?
| | Geography | 1 | 2013 | 81 | 0.450 |
Why?
| | Program Evaluation | 4 | 2023 | 374 | 0.430 |
Why?
| | Cooperative Behavior | 3 | 2018 | 254 | 0.400 |
Why?
| | Aged, 80 and over | 6 | 2023 | 3431 | 0.350 |
Why?
| | Neoplasms | 1 | 2019 | 1316 | 0.350 |
Why?
| | Palliative Care | 2 | 2020 | 188 | 0.320 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2018 | 19 | 0.320 |
Why?
| | Viscosupplements | 2 | 2017 | 12 | 0.310 |
Why?
| | Hyaluronic Acid | 2 | 2017 | 32 | 0.300 |
Why?
| | Propensity Score | 3 | 2022 | 137 | 0.280 |
Why?
| | Vancomycin | 2 | 2018 | 88 | 0.280 |
Why?
| | Time Factors | 6 | 2018 | 3213 | 0.280 |
Why?
| | Osteoarthritis, Knee | 2 | 2017 | 105 | 0.280 |
Why?
| | Acute Kidney Injury | 2 | 2021 | 403 | 0.240 |
Why?
| | Risk Factors | 4 | 2021 | 3935 | 0.230 |
Why?
| | Prevalence | 3 | 2022 | 1025 | 0.230 |
Why?
| | Emergency Service, Hospital | 2 | 2019 | 539 | 0.230 |
Why?
| | Pharmaceutical Services | 1 | 2024 | 57 | 0.230 |
Why?
| | Vaccines | 1 | 2023 | 65 | 0.220 |
Why?
| | Advance Care Planning | 1 | 2023 | 27 | 0.220 |
Why?
| | Pharmacy | 1 | 2024 | 64 | 0.220 |
Why?
| | Pharmacies | 1 | 2023 | 63 | 0.220 |
Why?
| | Developmental Disabilities | 1 | 2023 | 127 | 0.220 |
Why?
| | Intellectual Disability | 1 | 2023 | 149 | 0.210 |
Why?
| | Guideline Adherence | 1 | 2023 | 148 | 0.210 |
Why?
| | Neck Pain | 1 | 2021 | 8 | 0.200 |
Why?
| | Health Care Costs | 1 | 2022 | 171 | 0.200 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 127 | 0.200 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 164 | 0.200 |
Why?
| | Drug Prescriptions | 2 | 2021 | 89 | 0.200 |
Why?
| | Quality Improvement | 1 | 2023 | 245 | 0.200 |
Why?
| | Back Pain | 1 | 2021 | 44 | 0.200 |
Why?
| | Buprenorphine | 1 | 2023 | 132 | 0.200 |
Why?
| | Arthralgia | 1 | 2021 | 50 | 0.200 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 52 | 0.200 |
Why?
| | Education, Pharmacy | 1 | 2024 | 165 | 0.190 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2021 | 79 | 0.190 |
Why?
| | Morphine | 1 | 2021 | 96 | 0.190 |
Why?
| | Anti-Infective Agents | 1 | 2021 | 110 | 0.190 |
Why?
| | Afghan Campaign 2001- | 2 | 2018 | 49 | 0.190 |
Why?
| | Bacteremia | 1 | 2021 | 101 | 0.190 |
Why?
| | Amines | 1 | 2020 | 46 | 0.190 |
Why?
| | Drug Monitoring | 2 | 2018 | 85 | 0.190 |
Why?
| | Professional Role | 2 | 2018 | 88 | 0.180 |
Why?
| | Brain Neoplasms | 1 | 2023 | 284 | 0.180 |
Why?
| | Analgesics | 1 | 2020 | 106 | 0.180 |
Why?
| | Outpatients | 1 | 2020 | 123 | 0.180 |
Why?
| | Hydrocodone | 3 | 2024 | 17 | 0.170 |
Why?
| | Oxycodone | 3 | 2024 | 24 | 0.170 |
Why?
| | Health Promotion | 1 | 2022 | 300 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2023 | 596 | 0.170 |
Why?
| | Young Adult | 2 | 2019 | 4318 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 426 | 0.160 |
Why?
| | Critical Care | 2 | 2018 | 234 | 0.160 |
Why?
| | Motivation | 2 | 2018 | 291 | 0.160 |
Why?
| | Hematologic Tests | 1 | 2018 | 11 | 0.160 |
Why?
| | Hypotension | 1 | 2019 | 67 | 0.160 |
Why?
| | Anti-Bacterial Agents | 3 | 2021 | 820 | 0.160 |
Why?
| | Sepsis | 1 | 2021 | 251 | 0.160 |
Why?
| | Age Distribution | 1 | 2018 | 198 | 0.160 |
Why?
| | Physicians, Primary Care | 1 | 2018 | 43 | 0.150 |
Why?
| | Drug Interactions | 1 | 2018 | 206 | 0.150 |
Why?
| | Career Mobility | 1 | 2017 | 26 | 0.150 |
Why?
| | Lung Neoplasms | 1 | 2023 | 642 | 0.150 |
Why?
| | Bacterial Infections | 1 | 2018 | 105 | 0.150 |
Why?
| | Drug Utilization | 1 | 2017 | 74 | 0.150 |
Why?
| | Adolescent | 2 | 2019 | 6897 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 95 | 0.140 |
Why?
| | Penicillanic Acid | 1 | 2016 | 23 | 0.140 |
Why?
| | Logistic Models | 1 | 2019 | 995 | 0.140 |
Why?
| | Cephalosporins | 1 | 2016 | 32 | 0.140 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2017 | 282 | 0.140 |
Why?
| | Odds Ratio | 1 | 2018 | 604 | 0.140 |
Why?
| | Counseling | 1 | 2016 | 149 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 281 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2018 | 5604 | 0.130 |
Why?
| | Prospective Studies | 2 | 2018 | 2604 | 0.130 |
Why?
| | Primary Health Care | 1 | 2018 | 401 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2018 | 327 | 0.130 |
Why?
| | Patient Care Team | 1 | 2016 | 273 | 0.130 |
Why?
| | Pharmacy Service, Hospital | 1 | 2014 | 17 | 0.130 |
Why?
| | Prescription Drug Misuse | 1 | 2014 | 30 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2016 | 368 | 0.120 |
Why?
| | Community Health Services | 1 | 2014 | 115 | 0.120 |
Why?
| | Length of Stay | 1 | 2016 | 683 | 0.110 |
Why?
| | Drug Utilization Review | 1 | 2013 | 26 | 0.110 |
Why?
| | Obesity | 1 | 2022 | 1202 | 0.110 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 401 | 0.110 |
Why?
| | Hospitalization | 1 | 2016 | 705 | 0.100 |
Why?
| | Arkansas | 3 | 2022 | 2100 | 0.090 |
Why?
| | Organ Dysfunction Scores | 2 | 2017 | 17 | 0.080 |
Why?
| | Arterial Pressure | 2 | 2018 | 50 | 0.080 |
Why?
| | Injections, Intra-Articular | 2 | 2017 | 34 | 0.080 |
Why?
| | Orthopedic Procedures | 2 | 2017 | 82 | 0.070 |
Why?
| | Knee Joint | 2 | 2017 | 177 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2024 | 2387 | 0.060 |
Why?
| | Incidence | 2 | 2019 | 1082 | 0.060 |
Why?
| | Advance Directives | 1 | 2023 | 38 | 0.060 |
Why?
| | Veterans Health | 1 | 2023 | 75 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2023 | 204 | 0.050 |
Why?
| | Staphylococcus | 1 | 2021 | 33 | 0.050 |
Why?
| | Learning | 1 | 2024 | 175 | 0.050 |
Why?
| | Animals | 1 | 2017 | 14385 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 231 | 0.050 |
Why?
| | Child | 2 | 2023 | 7341 | 0.050 |
Why?
| | Epidemics | 1 | 2018 | 19 | 0.040 |
Why?
| | Inservice Training | 1 | 2018 | 41 | 0.040 |
Why?
| | History, 21st Century | 1 | 2018 | 62 | 0.040 |
Why?
| | Medicaid | 1 | 2021 | 267 | 0.040 |
Why?
| | History, 20th Century | 1 | 2018 | 114 | 0.040 |
Why?
| | Education, Nursing, Continuing | 1 | 2018 | 24 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2017 | 7 | 0.040 |
Why?
| | Physicians | 1 | 2021 | 247 | 0.040 |
Why?
| | Molecular Weight | 1 | 2017 | 100 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2018 | 141 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 232 | 0.040 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 68 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 150 | 0.040 |
Why?
| | Piperacillin | 1 | 2016 | 25 | 0.040 |
Why?
| | Research Design | 1 | 2018 | 374 | 0.040 |
Why?
| | Pain Measurement | 1 | 2017 | 246 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 514 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2016 | 319 | 0.030 |
Why?
| | Depressive Disorder, Major | 1 | 2017 | 159 | 0.030 |
Why?
| | Geriatrics | 1 | 2016 | 47 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 663 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2016 | 304 | 0.030 |
Why?
| | Societies, Medical | 1 | 2016 | 194 | 0.030 |
Why?
| | Substance Abuse Detection | 1 | 2014 | 92 | 0.030 |
Why?
|
|
Painter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|